顺铂联合紫杉醇同步放化疗治疗中晚期 宫颈癌的临床分析.docVIP

精品论文 参考文献 顺铂联合紫杉醇同步放化疗治疗中晚期 宫颈癌的临床分析 陈 静 孙志华 杨勇琴 ( 南京医科大学附属江苏省肿瘤医院 妇放科 南京 210009 ) 【摘要】 目的：观察紫杉醇、顺铂化疗联合放疗在中晚期宫颈癌患者中的临床效果。方法：48 例中晚期宫颈癌患者随机分为试验组和对照组，每组各24 例， 对照组采用常规外照射加腔内照射方法进行放疗；试验组在对照组治疗的基础上加用紫杉醇联合顺铂同步放化疗。观察两组患者的疗效和不良反应。结果：观察 组近期有效率高于对照组(P＜0.05)；观察组3 年生存率高于对照组(P＜0.05)；观察组消化道反应、骨髓抑制发生率高于对照组(P＜0.05)。结论：紫杉醇、顺铂化 疗联合放疗治疗中晚期宫颈癌疗效肯定，不良反应可以耐受。 【关键词】宫颈癌；顺铂；紫杉醇；放疗； 疗效 Clinical Study of Cisplatin Plus Paclitaxel Combined with Radiotherapy in Treatment of Advanced Cervix Cancer Chen Jing Sun Zhihua Yang Yongqin (Department of radiotherapy ,the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University ,Nanjing 210009 China) Abstract: Objective: To observe the clinical efficacy of paclitaxel plus cisplatin combined with radiotherapy in treatment of advanced cervix cancer.Methods: Forty-eight patients with local advanced cervical cancer were randomly divided into tested group ( 24 cases) and controlled group ( 24 cases) . The patients in controlled group were given concurrent radiotherapy while those in tested group were treated with concurrent radiotherapy plus paclitaxel and cisplatin .The clinical efficacy and side effect of the two groups were compared. Results:The total effective rates in short term , 3-year survival rates , gastrointestinal reaction and metastasis in the tested group were higher than those in the controlled group(Plt; 0.05).Conclusions: The clinical efficacy of concurrent radiotherapy plus paclitaxel and cisplatin was relatively good on patients with advanced cervical cancer and the side effects are well tolerated. Key words: Cervix Cancer； Cisplatin； Paclitaxel； Radiotherapy;Clinical Efficacy 宫颈癌是女性最为常见的恶性肿瘤之一，而且大部分患者首次 诊断时已是中晚期，对Ⅱb 期以上的中晚期患者，目前公认的治疗手 段为同步放化疗可以明显改善宫颈癌患者的生存质量，提高肿瘤的 局部控制率，降低远处转移率，与单纯放疗相比，以顺铂为基础的 同步放化疗使死亡风险下降了30%-50%， 可以改善患者的无进展生 存和总生存[1]。本研究采用同步放疗联合紫杉醇+顺铂治疗宫颈癌， 其临床效果满意。现报告如下： 1 资料与方法 1.1 临床资料 2009年1月至2010年2月我院收治的中晚期宫颈癌患者48例， 均经临床和病理确诊，且为首次治疗，Karmofsky 评